Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$3.91 USD
+0.03 (0.77%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $3.99 +0.08 (2.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 17 |
Average Target Price | $13.86 |
LT Growth Rate | 10.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.74 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 8 | 8 | 8 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.12 | 2.12 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/13/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Hold | Hold |
8/8/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
8/7/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
8/7/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
6/18/2024 | Not Identified | Not Identified | Hold | Hold |
6/16/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
5/30/2024 | Evercore Partners | Liisa A Bayko | Not Available | Hold |
5/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Hold | Hold |
5/9/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.